secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLUS THERAPEUTICS, INC. (PSTV)
CIK:        0001095981
Form:       8-K
Filed at:   2023-10-31T23:59:59+00:00
Accession:  0001193125-23-267200
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Plus Therapeutics Q3 net loss $3.2M ($1.00/share); cash $11M, runway into 2025
------------------------------------------------------------------------------

- Net loss $3.2M ($1.00 per share) vs $5.2M ($2.85) in Q3 2022; operating expenses $4.5M.
- Cash $11M at Sep 30, 2023; plus $10.2M expected from CPRIT grant through 2024, providing runway into 2025.
- Completed dosing in Cohort 4 of Phase 1 ReSPECT-LM trial; new survival data from Phase 2 ReSPECT-GBM to be presented at SNO Nov 2023.
- Appointed Pius Maliakal, Ph.D. as VP of Clinical Operations; transferred CNSide biomarker assay from Biocept.
- Grant revenue $1.2M in Q3 from CPRIT; total grant awards $3M from NIH and $17.6M from CPRIT.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1095981/000119312523267200/0001193125-23-267200-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1095981/000119312523267200/d578460d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-267200

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer